



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/773522/2010

European Medicines Agency decision

P/291/2010

of 22 December 2010

on the granting of a product specific waiver for ranibizumab (Lucentis), (EMEA-000527-PIP02-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/291/2010

of 22 December 2010

on the granting of a product specific waiver for ranibizumab (Lucentis), (EMA-000527-PIP02-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Novartis Europharm Limited on 4 June 2010 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 November 2010 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A waiver for ranibizumab (Lucentis), solution for injection – single-use vial, solution for injection – single-use pre-filled syringe, intravitreal use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Novartis Europharm Limited, Wimblehurst Road, Horsham, RH12 5AB, United Kingdom.

Done at London, 22 December 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/PDCO/655853/2010

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-000527-PIP02-10

Scope of the application

Active substance(s):

Ranibizumab

Invented name:

Lucentis

Condition(s):

Treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection – single-use vial

Solution for injection – single-use pre-filled syringe

Route(s) of administration:

Intravitreal use

Name/corporate name of the PIP applicant:

Novartis Europharm Limited

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted to the European Medicines Agency on 4 June 2010 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 15 July 2010.

Supplementary information was provided by the applicant on 1 October 2010.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 12 November 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age for solution for injection - single-use vial and for solution for injection - single-use pre-filled syringe, intravitreal use on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

Treatment of neovascular (wet) age-related macular degeneration (AMD)

EU Number	Invented name	Strength	Pharmaceutical form	Route of administration	Packaging	Content (concentration)	Package size
EU/1/06/374/001	Lucentis	10 mg/ml	Solution for injection	Intravitreal use	Vial (glass)		1 vial